Health services research in patients with breast cancer (CAMISS-prospective): study protocol for an observational prospective study

García-Gutiérrez, Susana; Orive, Miren; Sarasqueta, Cristina; Legarreta, María José; González, Nerea; Redondo, Maximino; Rivero-Santana, Amado; Serrano‐Aguilar, Pedro; Castells, Xavier; Quintana, José M.; Sala, María

doi:10.1186/s12885-017-3926-9

Cited by 11 publications

(23 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Waiting for treatment is one of the events that produces most stress among patients and delay is one of their most frequent causes of complaint (14). Unlike previous research in this field, the present study prospectively evaluates a large number of patients diagnosed and treated in different public-sector hospitals (15). Over half of our study sample experienced STD.…”

Section: Discussionmentioning

confidence: 99%

Factors that Influence Treatment Delay for Patients with Breast Cancer

Padilla‐Ruiz¹,

Zarcos‐Pedrinaci²,

Rivas-Ruiz³

et al. 2020

Ann Surg Oncol

Self Cite

View full text Add to dashboard Cite

The diagnosis or treatment of breast cancer is sometimes delayed. A lengthy delay may have a negative psychological impact on patients. Our study aim is to evaluate the sociodemographic, clinical and pathological factors associated with delay in the provision of surgical treatment for localised breast cancer, in a prospective cohort of patients. MethodThis observational, prospective, multicentre study was conducted in ten hospitals belonging to the Spanish national public health system, located in four Autonomous Communities (regions). The study included 1236 patients, diagnosed through a screening programme or found to be symptomatic, between April 2013 and May 2015. The study variables analysed included each patient's personal history, care situation, tumour history and data on the surgical intervention, pathological anatomy, hospital admission and follow-up.Treatment delay was defined as more than 30 days elapsed between biopsy and surgery. ResultsOver half of the study population experienced surgical treatment delay. This delay was greater for patients with no formal education and among widows, persons not requiring assistance for usual activities, those experiencing anxiety or depression, those who had a high BMI or an above-average number of comorbidities, those who were symptomatic, who did not receive NMR spectroscopy, who presented a histology other than infiltrating ductal carcinoma or who had poorly-differentiated carcinomas. ConclusionsCertain sociodemographic and clinical variables are associated with surgical treatment delay. This study identifies factors that influence surgical delays, highlighting the importance of preventing these factors and of raising awareness among the population at risk and among health personnel.

show abstract

Section: Discussionmentioning

confidence: 99%

Factors that Influence Treatment Delay for Patients with Breast Cancer

Padilla‐Ruiz¹,

Zarcos‐Pedrinaci²,

Rivas-Ruiz³

et al. 2020

Ann Surg Oncol

Self Cite

View full text Add to dashboard Cite

show abstract

“…All patients provided written informed consent to be admitted in the study. The standard diagnosis workflow [ 44 ] used in this study followed the recommendation of the European Guidelines for Quality Assurance in breast cancer screening and diagnosis [ 45 ]. All the experiments were conducted according to the principles expressed in the Declaration of Helsinki.…”

Section: Methodsmentioning

confidence: 99%

Discovery and Proof-of-Concept Study of Nuclease Activity as a Novel Biomarker for Breast Cancer Tumors

Hernandez

Araúzo-Bravo

Gerovska

et al. 2021

Cancers

View full text Add to dashboard Cite

Breast cancer is one of the most common pathologies diagnosed in the clinical practice. Despite major advancements in diagnostic approaches, there is no widely accepted biomarker in the clinical practice that can diagnose breast malignancy. Confirmatory diagnosis still relies on the pathological assessment of tissue biopsies by expert pathologists. Thus, there is an unmet need for new types of biomarkers and novel platform technologies that can be easily and robustly integrated into the clinic and that can assist pathologists. Herein, we show that nuclease activity associated to malignant tumors can be used as a novel biomarker in breast cancer, which can be detected via specific degradation of nucleic acid probes. In this study we have identified a set of three chemically modified nucleic acid probes that can diagnose malignancy in biopsy samples with high accuracy (89%), sensitivity (82%) and specificity (94%). This work represents a breakthrough for the potential clinical use of nuclease activity as biomarker, which can be detected via nucleic acids probes, for the clinical diagnosis of malignancy in breast tissue biopsies. This platform technology could be readily implemented into the clinic as adjunct to histopathological diagnostic.

show abstract

“…1,2 Unlike previous research in this field, the present study prospectively evaluates a large number of patients diagnosed and treated in different public-sector hospitals. 3 Sociodemographic parameters, clinical characteristics and lifestyle habits were studied. 4 PRESENT Over half of the study population experienced surgical treatment delay ([ 30 days).…”

Section: Pastmentioning

confidence: 99%